Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional)

The Department of Health and Human Services, through the National Institutes of Health, announces a funding opportunity aimed at advancing research for rare diseases through the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative seeks applications for new and renewed funding to enhance diagnosis, management, and treatment of rare diseases, focusing on patient-centric, multi-site, and collaborative research. The funding aims to address significant public health challenges associated with over 10,000 rare diseases in the U.S., which currently lack effective treatments. Key support structures include a Data Management and Coordinating Center (DMCC) to facilitate data sharing, standardization, and support, along with significant involvement from patient advocacy groups. Each RDCRC must engage in at least one longitudinal study, emphasizing the importance of understanding disease progression to support effective clinical trials. The program encourages innovative approaches and collaboration across various stakeholders, aligning with similar efforts from participating NIH institutes. The goal is to foster research that moves towards clinical trial readiness, leveraging existing knowledge and promoting the rapid development of treatments for rare diseases.

The National Center for Advancing Translational Sciences (NCATS) plans to re-issue the Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) within the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to advance research on rare diseases by encouraging collaborative, multi-site, patient-centered clinical trials. The upcoming NOFO, released on May 5, 2025, invites applications focused on at least three distinct rare diseases and requires each consortium to propose two to four clinical research projects, including one longitudinal study. Key areas of focus include early-stage clinical trials, biomarker studies, and the development of patient-reported outcomes. Applications must emphasize collaborative, multidisciplinary efforts that involve patients, clinicians, researchers, and other stakeholders. The document outlines eligibility criteria for various organizations and emphasizes that awarded projects will support research activities significantly involving NIH program staff. The funding framework will depend on available resources, with specific areas of interest determined at the time of the NOFO publication. This effort aims to foster innovative approaches to enhance the development of effective treatments and interventions for individuals affected by rare diseases.